After verifying these antibodies depleted ST2+ Treg cells by inducing apoptosis and inhibiting proliferation, we showed in multiple models of leukemia that increased antitumoral activity occurred with a decrease in CD8+ T cell exhaustion and restoration of type 1 immunity, extending survival. Here, IL1RL1 is linked to leukemia.